Notably, fam-trastuzumab deruxtecan is an option for patients who received prior HER2-directed therapy; however, the cohort included only patients with HER2 IHC 3+, and patients must be monitored closely for the potential serious side effect of interstitial lung disease [64]. This evidence concerns the gene ERBB2 and interstitial lung disease.